Clinical Trials

Sponsor: National Cancer Institute

Sponsor Study ID: 5P01CA203628

Study Title: A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients with Prostate Cancer Progression on Enzalutamide or Abiraterone

NCT Number: NCT04207255

Phase: II

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Prostate

Study Objectives: This is a Phase II efficacy study of opaganib in patients with metastatic castration-resistant prostate cancer (mCRPC) that is progressing during treatment with androgen signaling blockers abiraterone or enzalutamide.

If you would like to contact a MUSC study team member to learn more information about this study, click HERE.